BriaCell Therapeutics Closes $4.7M Offering, Securing Critical Working Capital
Summary
BriaCell Therapeutics announced the closing of its best-efforts offering, raising approximately $4.7 million in gross proceeds from the sale of 1.45 million common shares at $3.25 per share. This capital infusion is critical for the company, which disclosed a going concern warning in its March 10th 10-Q filing. The funds will be used for working capital and general corporate purposes, providing essential liquidity for its operations. This news follows the offering's pricing announcement on May 31st and an SEC filing earlier today that finalized the terms.
At the time of this announcement, BCTX was trading at $3.27 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.7M. The 52-week trading range was $2.98 to $36.90. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.